A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.
about
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing programCharacterization and drug resistance patterns of Ewing's sarcoma family tumor cell linesAberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancerMembrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cellsInitial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).Initial testing of topotecan by the pediatric preclinical testing program.Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.Synthesis, characterization, DNA binding and cleavage, BSA interaction and anticancer activity of dinuclear zinc complexes.Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramInitial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testingThe glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing programInitial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing programMetabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines.Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing programInitial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteinsInitial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing programEfficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia
P2860
Q24627862-3F8B265D-D369-4DDF-90BC-F717CEEEDFDDQ28535586-5A735CC5-648F-4ABA-BFAB-E3A0810BC864Q28543351-9074E5B8-155A-4B54-8CE8-CE12711D6022Q33783162-3BC707BA-F61A-41EE-A338-D8E25AD09DA6Q33867046-5709CD6A-CB10-4E48-AACD-8B3BF9B2583FQ34073784-98A83ABE-0031-4FA0-B8C4-FA97075043B0Q34323880-3D65B75C-28D1-4E1A-A960-E44C9D205BB8Q34344177-AC27751E-0909-48C5-BC9F-017879953DC3Q34361391-6C324131-9F43-460B-BDAB-5AFE846E8C00Q34396926-74D2C4BA-4200-4DA7-B0DA-546497F20DA0Q34414710-368FEA1D-F375-4F90-80F0-FE372D17B28FQ34414736-DE2D1D11-34E7-4E21-A732-DFF99CE8B4C3Q34415484-B65178CC-E15A-44B0-90B6-DA4AB7628926Q34422537-F56D8F61-152B-4039-BDD4-36EF6A8A815DQ34448863-D67E7A3E-97BE-499A-87E4-1B511C23BAC4Q34475748-436FA495-4055-4C24-8F3A-C526C417433AQ34475754-001C883A-3596-437F-AA66-1A6D8E85A784Q34561518-FB89F0EA-5F1F-4BAB-85FC-4EC5E3AF865DQ34592429-8334D2B9-CD27-4E89-AFCE-A4A39D9FDF83Q34660299-E12EA929-E360-4705-B03F-838444681495Q34683782-4BB98A40-FC48-415C-9EE4-9CF0EC5843A1Q34683835-F753862E-B718-47CB-8BE9-F9900ED1B181Q34953372-DE35E7C0-5637-4B5B-972E-08926D7AE49AQ34990343-CCC310CB-3033-4F33-ABD9-1EE296835B64Q35005290-5E9A5A57-B7E0-4ECF-BF4A-55EDF7DE10AFQ35005309-4A9E58BF-072D-49B7-9527-4482C6570098Q35046326-E309BFF1-5928-4410-B083-1397868A65D1Q35159149-3A1F8F78-B4C1-4E6B-8944-C8E4E0AFCA8BQ35161137-8A8561E5-2AC6-4AE2-AF56-3799F3124ED1Q35186275-390301C4-75EB-48D3-A91E-DA1BA42EB6F9Q35238042-F1D612E8-1A10-4330-9523-14510B7F25F7Q35513763-B5A3E602-ACE7-4064-BE49-AEBF1F2686C2Q35549470-98683C07-B881-4A46-B1C6-59CC98B364E8Q35659461-6E7E1E21-35D5-4C79-A370-8FA30AB8D87DQ35684995-1312C595-AA83-4D40-833A-9A7610BCF13AQ35748503-EC4720B0-C131-4E6C-81F2-7A7E91287056Q35791105-7694665E-21CA-4695-B014-6D961F506AECQ35857060-DC1BC5CB-9015-4170-93D1-606DE4FE0D39Q35951806-D26D9BED-6D95-45A9-BA86-14C4F9F0683CQ35999183-ACD17FBD-ADC6-4607-9B5D-D973B0C9E59A
P2860
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A fluorescence microplate cyto ...... synergistic drug combinations.
@en
A fluorescence microplate cyto ...... synergistic drug combinations.
@nl
type
label
A fluorescence microplate cyto ...... synergistic drug combinations.
@en
A fluorescence microplate cyto ...... synergistic drug combinations.
@nl
prefLabel
A fluorescence microplate cyto ...... synergistic drug combinations.
@en
A fluorescence microplate cyto ...... synergistic drug combinations.
@nl
P2093
P1476
A fluorescence microplate cyto ...... synergistic drug combinations.
@en
P2093
C Patrick Reynolds
Robert T Proffitt
Tomas Frgala
P304
P356
10.1158/1535-7163.MCT-04-0331
P577
2007-03-01T00:00:00Z